武田薬品工業株式会社
OSAKA, Japan, August 2, 2024 – Takeda Pharmaceutical Company Limited (“Takeda”) today outlined a high-level overview of planned changes to its business operation structure across the Japan Pharma Business Unit (JPBU) and provided future directions in its Research & Development (R&D) Japan organization. These changes are part of the company’s multi-year enterprise-wide efficiency program announced on May 9, designed to enhance agility in response to the evolving business environment and ensure the sustainable delivery of life-transforming treatments to patients worldwide. This initiative is also expected to achieve procurement savings and drive advancements in data, digital, and technology (DD&T) capabilities.
In Japan, Takeda has strengthened its operating model through the acquisition and integration of Shire and Nihon Pharmaceutical and today the company is providing innovative medicines, including plasma-derived therapies, to more people in need. Our ways of working worldwide have evolved significantly including in Japan, and rapid advancement of AI and the diversification of information channels are making significant impact for patients and health care providers. We are experiencing an increasingly challenging landscape for the pharmaceutical industry, which is characterized by a declining birthrate, an aging population and pressure to manage medical costs. Also, in recent years, the company’s business processes and adoption of novel technologies have improved collaboration with key stakeholders including patients, health care providers and regulatory authorities.
Following a careful review of its business operations and structure in Japan, the company shared the following planned future changes which may include some impacts to some roles for Japan-based employees within JPBU and R&D Japan organization.
JPBU’s Vision
JPBU has aligned on a set of strategic pillars for the future organization. These include:
With these pillars in mind, the Company will streamline operations and organize the JPBU team across two divisions: one that will enhance our ability to drive new sources of growth with a focus on new medicines, and a second that will improve access to our existing anchor therapies for more patients and strengthen our foundation for future investment.
With these changes, Takeda aims to further strengthen collaboration and cooperation among teams across the JPBU and sharpen areas of expertise, while maintaining highly specialized and domain-specific expertise within each disease area. In addition, the company will prioritize investments and upskilling related to data, digital and technology to meet the current and future needs of patients and healthcare professionals.
We will continue refining the details of our organizational structure, and provide additional potential updates as necessary.
Advancing a Promising Late-Stage Pipeline and sustaining innovation
Takeda is advancing an exciting late-stage pipeline and aligned with Takeda’s multi-year efficiency program, the Global R&D organization is implementing a number of changes to support swift and efficient delivery of this pipeline, while also ensuring a sustainable flow of innovation from early research through clinical development in the future. The anticipated changes to the R&D organization in Japan follow decisions and changes that are being implemented already in the U.S., Europe, Asia and other parts of world, while maintaining the R&D base functions in Shonan and Osaka. As always, teams will work diligently to minimize disruption and will act in a manner that treats all employees with dignity and respect.
As part of Takeda’s organization evolution in Japan, the JPBU and R&D Japan are planning to offer eligible employees within these groups the option to participate in a "Future Career Program," designed to support individuals who wish to retire or transition out of Takeda. The details of this program will be discussed with Takeda Labor Union in Japan and determined in due course.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Tsuyoshi Tada
[email protected]